Phase II data report a pathologic complete response in patients who received radiotherapy after neoadjuvant therapy without surgery, when selected by image-guided vacuum-assisted core biopsy

Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups

Encouraging preliminary results are reported with innovative antibody–drug conjugate designs, but underlying mechanisms of action still need to be described to improve efficacy and tolerability 

In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types

Efficacy of PD-1 inhibitors in this setting reflects that reported in triple-negative breast cancer and is confirmed by long-term data presented at the ESMO Congress  

The study involved patients with HR-positive/HER2-negative localised disease, but additional analyses are required to describe implications for clinical practice.

Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer  

Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs  

In her keynote lecture, recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz talks of the need to challenge accepted paradigms to progress clinical research